SCHEMBL21859863

SCHEMBL21859863

CCC1CCc2cccc(Cl)c21

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 2/20 0.45
HTR1A P08908 3/20 0.39
HTR7 P34969 3/20 0.39
HTR5A P47898 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
TAS1R3 Q7RTX0 2/20 0.37
TAS1R1 Q7RTX1 2/20 0.37
TAS1R2 Q8TE23 2/20 0.37
ESR1 P03372 1/20 0.36
ESR2 Q92731 1/20 0.36
DRD2 P14416 1/20 0.36
ADRA2A P08913 1/20 0.36
CYP2D6 P10635 1/20 0.36
ADRA2B P18089 1/20 0.36
ADRA2C P18825 1/20 0.36
ADRA1D P25100 1/20 0.36
ADRA1A P35348 1/20 0.36
ADRA1B P35368 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13948528 0.79 DRD2 (0.40) HTR1AHTR7DRD2
SCHEMBL15286668 0.77 GLA (0.41) HTR2CHTR1ATAS1R3TAS1R1TAS1R2
SCHEMBL10246287 0.76 DRD2 (0.55) HTR1ADRD2
SCHEMBL15577042 0.76 HTR2C (0.62) HTR2CHTR1AHTR7HTR5ATAS1R3
SCHEMBL13198466 0.76 HTR2C (0.62) HTR2CHTR1AHTR7HTR5ATAS1R3
SCHEMBL10247633 0.73 DRD2 (0.33) HTR2CHTR1ADRD2
SCHEMBL1151104 0.72 HTR2C (0.45) HTR2C
SCHEMBL16395308 0.72 HTR2C (0.45) HTR2C
SCHEMBL16395441 0.72 HTR2C (0.45) HTR2C
SCHEMBL18204541 0.72 HTR2C (0.45) HTR2CTDP1L3MBTL1TAS1R3TAS1R1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10604507-B2 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof Crinetics Pharmaceuticals, Inc. (US) 2020-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10604507-B2 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof MC3R, MC1R, MC2R HTR2C 31/4885HTR1A 95/4885HTR7 121/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.